Nasdaq Approves Listing of IMV Inc. Common Shares
May 31 2018 - 7:05AM
IMV Inc. (“IMV” or the “Corporation”) (TSX:IMV) (OTCQX:IMMVD), a
clinical stage immunotherapy company, today announced that its
common shares have been approved for listing on the Nasdaq Capital
Market under the symbol "IMV." Trading will commence as early as
Friday, June 1, 2018. The Corporation will retain its listing on
the Toronto Stock Exchange under the symbol "IMV" and the company's
common shares will continue to trade on the OTCQX under the symbol
“IMMVD” until trading on the Nasdaq commences.
Frederic Ors, IMV Chief Executive Officer,
commented, “On the heels of recent progress we have made in
positioning and validating IMV’s unique value proposition in
immuno-oncology, listing on Nasdaq affords us the opportunity to
attract more institutional investors, broaden our shareholder base,
and improve liquidity. We celebrate this milestone and look forward
to continuing our track record of clinical progress and corporate
advancement.”
About IMV
IMV Inc. is a clinical stage biopharmaceutical
company dedicated to making immunotherapy more effective, more
broadly applicable, and more widely available to people facing
cancer and other serious diseases. IMV is pioneering a new class of
immunotherapies based on the Company’s proprietary drug delivery
platform. This patented technology leverages a novel mechanism of
action that enables the reprogramming of immune cells in vivo,
which are aimed at generating powerful new synthetic therapeutic
capabilities. IMV’s lead candidate, DPX-Survivac, is a T cell
activating immunotherapy that combines the utility of the platform
with a target: survivin. IMV is currently conducting three Phase 2
studies with Incyte and Merck assessing DPX-Survivac as a
combination therapy in ovarian cancer and diffuse large B-cell
lymphoma. Connect at www.imv-inc.com.
IMV Forward-Looking Statements
This press release contains forward-looking
information under applicable Canadian and U.S. securities law. All
information that addresses activities or developments that we
expect to occur in the future is forward-looking information.
Although the Corporation believes the forward-looking statements in
this press release are reasonable, it can give no assurance that
the expectations and assumptions in such statements will prove to
be correct. The Corporation cautions investors that any
forward-looking statements by the Corporation are not guarantees of
future results or performance, and that actual results may differ
materially from those in forward-looking statements as a result of
various factors, including, but not limited to, the matters
discussed under “Risk Factors and Uncertainties” in IMV’s Annual
Information Form filed on March 20, 2018. IMV Inc. assumes no
responsibility to update forward-looking statements in this press
release except as required by law.
Contacts for IMV:
MEDIA Mike Beyer, Sam Brown Inc.
T: (312) 961-2502 E: mikebeyer@sambrown.com
INVESTOR RELATIONS Pierre Labbé,
Chief Financial Officer T: (902) 492-1819 E: info@imv-inc.com
Patti Bank, Managing Director, Westwicke
Partners O: (415) 513-1284 T: (415) 515-4572 E:
patti.bank@westwicke.com
IMV (TSX:IMV)
Historical Stock Chart
From Jun 2024 to Jul 2024
IMV (TSX:IMV)
Historical Stock Chart
From Jul 2023 to Jul 2024